AstraZeneca

AstraZeneca is a global pharmaceutical company that has shaped its R&D philosophy around a "5R" framework — the right target, right tissue, right safety, right patient, and right commercialization — which it began applying to internal drug development as early as 2014 and published in 2019, reportedly raising project success rates from 4% to 19% . The company has since become an active dealmaker in next-generation therapies: in March 2025 it acquired Belgian biotech EsoBiotec for $1 billion to enter in vivo CAR-T cell therapy , and that same month partnered with Syneron Bio to develop first-in-class macrocyclic peptide drugs for chronic diseases using the latter's Synova platform . AstraZeneca has also pursued metabolic disease collaborations, including a three-year R&D pact with Kelan Pharma announced in June 2023 targeting hypercholesterolemia , and is named among major multinationals — alongside Novartis, BMS, Eli Lilly, and J&J — building positions in radiopharmaceuticals through M&A and strategic partnerships .